Zynex (ZYXI) Company Overview

Zynex Inc (NASDAQ:ZYXI) continues to expand its portfolio of innovative, non-invasive medical devices targeting pain management, rehabilitation, and pain monitoring.   The company's flagship NexWave product is a multi-modality electrotherapy device that combines various therapeutic modalities to provide effective pain relief.

VA Spending on Hospital and Medical Care Exceeds $112 Billion Annually ENGLEWOOD, Colo. , Dec. 17, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced a new partnership to conduct business with Veterans Affairs Medical Centers (VAMCs) across the United States.

Zynex Inc (NASDAQ:ZYXI) CEO Thomas Sandgaard spoke with Proactive about the company's 2024 achievements and plans for 2025. Zynex reached $200 million in revenue while staying profitable, thanks to employee dedication and innovative pain management products like braces and cold therapy devices.

ENGLEWOOD, Colo. , Dec. 12, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced highlights from a recent study comparing its NiCO™ laser pulse oximeter to conventional LED pulse oximeters for the effects of skin pigmentation on SpO2 measurements conducted by the University of California, San Francisco (UCSF) Hypoxia Lab.

Zynex announces the completion of the clinical verification trial of its NiCO pulse oximeter.

ENGLEWOOD, Colo. , Dec. 5, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it has completed its clinical verification trial for their NiCO™ pulse oximeter overseen by anesthesiologist Dr. David MacLeod at Duke University.

ENGLEWOOD, Colo. , Dec. 3, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced its membership in the Collaborative Community of the independently led Open Oximetry Project as an industry member.

Zynex Inc (NASDAQ:ZYXI) holds a competitive niche in the pain management market, benefiting from its focus on non-invasive, reimbursable solutions. While the company has successfully capitalized on the growing demand for non-opioid therapies, staying ahead will depend on its ability to innovate and adapt to a rapidly evolving medical device landscape.

Zynex Inc. (ZYXI) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to earnings of $0.10 per share a year ago.